Barclays
ORTX

Barclays’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Barclays’s Portfolio ORTX Stock Details ORTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200
Closed -$1.04K – 4754
2023
Q2 		$1.04K Hold
200
– – ﹤0.01% 4359
2023
Q1 		$1.07K Hold
200
– – ﹤0.01% 4923
2022
Q4 		$742 Hold
200
– – ﹤0.01% 5137
2022
Q3 		$1K Hold
200
– – ﹤0.01% 4722
2022
Q2 		$1K Hold
200
– – ﹤0.01% 4963
2022
Q1 		$1K Hold
200
– – ﹤0.01% 4860
2021
Q4 		$3K Sell
200
-132
-40% -$2.18K ﹤0.01% 4041
2021
Q3 		$8K Buy
332
+119
+56% +$3.54K ﹤0.01% 4557
2021
Q2 		$10K Sell
213
-14
-6% -$780 ﹤0.01% 4658
2021
Q1 		$17K Buy
227
+5
+2% +$355 ﹤0.01% 4396
2020
Q4 		$10K Buy
222
+10
+5% +$448 ﹤0.01% 4755
2020
Q3 		$8K Buy
212
+200
+1,667% +$10.3K ﹤0.01% 5039
2020
Q2 		$1K Sell
12
-196
-94% -$18K ﹤0.01% 5479
2020
Q1 		$16K Sell
208
-18
-8% -$2.07K ﹤0.01% 5714
2019
Q4 		$32K Sell
226
-1,317
-85% -$160K ﹤0.01% 5874
2019
Q3 		$183K Buy
1,543
+926
+150% +$129K ﹤0.01% 5036
2019
Q2 		$87K Buy
617
+605
+5,042% +$106K ﹤0.01% 5794
2019
Q1 		$2K Buy
12
+2
+20% +$301 ﹤0.01% 6875
2018
Q4 		$2K Buy
+10
New +$1.49K ﹤0.01% 6751

Other funds holding ORTX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays's ORTX Position: Q3 2023 in Review

Barclays sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q3 2023, closing a stake of 200 shares — an estimated $1.04K sold.

Barclays first reported a position in ORTX in Q4 2018 and held it in 19 quarters. The position peaked at $183K in Q3 2019. 32 funds tracked by Wall St. Rank hold ORTX as of Q3 2023.

  • Barclays reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q3 2023 after selling out during the quarter.
  • Barclays sold 200 Orchard Therapeutics plc American Depositary Shares shares in Q3 2023, an estimated $1.04K.
  • Barclays first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2018 and held it in 19 quarters.
  • Barclays's Orchard Therapeutics plc American Depositary Shares position peaked at $183K in Q3 2019.
  • 32 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.